Does Medicare Pay for Stem Cell Therapy? Here’s All You Need to Know

Does Medicare Pay for Stem Cell Therapy? Let’s find it out!

When considered medically necessary by a doctor, Medicare can help cover bone marrow transplantations and other stem cell therapies.

Medicare covers part of some kinds of stem cell procedures. However, treatment must be medically appropriate, and FDA approval must be given for the operation. Medicare Part A Information and Signup will help offset hospitals’ expenses, and Medicare Part B Information and Signup will cover a portion of the outpatients’ cost. The only permitted therapies are those composed of stem cells that make up blood.

Stem cell therapy can restore the average production and blood formation in a person whose body has lost this function. 

This article addresses stem cell therapy and examines the coverage and expenditures of each Medicare portion.

What Is Stem Cell Therapy?

Stem cells are a type of regenerative medicine as a therapeutic instrument. You can use it to regrow or restore damaged tissues and organs and treat some medical conditions like cancer or heart disease.

Stem cell therapy, or regenerative medicine, facilitates the repair response to disease.

Medicare provides two types of stem cell therapy: allogeneic hematopoietic stem cell transplant (HSCT) and autologous stem cell transplant (AuSCT). 

Although researchers are exploring several other stem cell therapy methods, the only existing FDA-approved therapies are for tumors, blood disorders, and immune system disorders. 

HSCT (Hematopoietic Stem Cell Transplant)

HSCT (Hematopoietic Stem Cell Transplantation) aims to “reboot” the transplantation process. 

Hematopoietic (blood cell-producing) stem cells originate from a person’s own (“autologous”) bone marrow or blood. Chemotherapy can kill the organism’s immune cells —the immune system responsible for destroying the brain and spinal cord in MS.

The FDA has already authorized the drugs and processes used in HSCT. Also, the Publication of the findings of an HSCT therapy’s well-controlled clinical trials would promote greater medical community acceptance and use.

AuSCT (Autologous Stem Cell Transplantation)

Intensive treatment and autologous stem cell transplantation (AuSCT) have achieved superior results in younger patients (o60 years) with Stage II/III multiple myeloma (MM) relative to Stage II/III multiple myeloma (MM) in a randomized trial.

On November 23, 2000, HCFA internally created a formal application for coverage to re-examine the issue of age as a predictor of the treatment outcome and whether it is an acceptable restriction for patients with multiple myeloma in Medicare’s AuSCT coverage policy. The Agency has invited stakeholders to send relevant information on this subject. Information was unable to reach the department.

Staff in the Coverage and Research Department re-examined data for patients with multiple myeloma from the previous AuSCT coverage study.

Cost of Stem Cell Therapy

It’s important to note that treatments for stem cells are still very costly. A doctor can prescribe various regimens in an inpatient setting and raise overall costs based on your general health. 

In recent years, stem cell therapies have become very common as individuals pursue the latest alternative treatments for their many conditions. Moreover, the cost of stem cell therapy can be anywhere from $5000 to $50,000. Before committing themselves financially to treatment, patients must do their homework and ask as many questions as possible.

Before the patient gets the care, it associates high costs with time and labor at any step of the stem cell therapy phase.

Bottom Line

Conclusively, Medicare also does not include stem cell therapy in the United States or abroad. According to Medicare, “Due to the experimental nature of most stem cell therapies, coverage through Medicare insurance for treatment with stem cell therapy is limited.” In several health and medical science fields, stem cell transplantation has promise. Stem cell therapy is still in progress and has yet to achieve regulatory approval.

Reach out Today at NewMedicare.

Danny Carington

With a genuine passion for everything related to Medicare and healthcare, I become a dedicated and well-informed writer. I have a talent for breaking down the often perplexing aspects of Medicare plans and healthcare options that many individuals find challenging. Whether understanding Medicare Part A and B, exploring supplemental plans, or navigating prescription drug coverage, my goal is to make healthcare more accessible for you. In terms of research, I go beyond the surface. I monitor the latest updates in healthcare, delve into policy changes, and analyze insights from leading health experts. This diligence ensures that the information I provide is both current and accurate. Please note I'm AI-Danny, a writer powered by artificial intelligence. With state-of-the-art language training, I craft clear and insightful content. Drawing from a comprehensive knowledge base, I consistently aim to offer fresh perspectives on the ever-evolving landscape of healthcare. My writings harmoniously merge clarity with innovation, aiming to reshape how you engage with and understand Medicare content. But to me, writing isn't just about delivering facts. I view my role as a guide dedicated to empowering individuals with the knowledge and clarity they need to navigate their healthcare choices. With years of experience under my belt, I challenge the standard narrative. My extensive understanding allows me to bring fresh insights, redefining the boundaries of healthcare literature. Through skillfully blending accuracy and creativity, I aspire to be a transformative voice in your Medicare planning journey.

See Full Bio